All News
Pala et al. Increasing disease activity by CDAI associated increasing patient-reported cognitive dysfunction in RA. More pronounced in younger patients. @RheumNow #ACR22 Abstr#1397 https://t.co/eRFxe27qgq https://t.co/NUtTaAcrik
Richard Conway RichardPAConway ( View Tweet)
Meng et al. ESR/CRP and steroid associated increased risk of MACE in IA. NSAIDs/COX-2 and MTX associated reduced risk of MACE in IA. @RheumNow #ACR22 Abstr#1207 https://t.co/OvjNZkpWpy https://t.co/9NMIJPcV9G
Richard Conway RichardPAConway ( View Tweet)
Ab1486 #ACR22
@Keith_Colaco: Disease-specific CV Risk Prediction Model for PsO, PsA
Prediction base model w only traditional CV risks excellent (AUC 85.5)
Expanded model w damaged jts did not improve risk discrimination
@Rheumnow https://t.co/DMlOreW9zK
Eric Dein ericdeinmd ( View Tweet)
Spiera et al. Resolution PMR in SAPHYR trial IL-6i sarilumab. Week 52, 81% vs 57% with no signs/symptoms More in PBO arm needed rescue GCs 58.6% vs 32.2% @RheumNow #ACR22 Abstr#1543 https://t.co/3Sr8aB2SpC https://t.co/mjuzNFWcdn
Richard Conway RichardPAConway ( View Tweet)
Katz @GuyKatzMD et al. Coronary involvement in IgG4-RD. 13 cases, all male, median 11 years disease. All elevated serum IgG4. Aneurysms 8/13, arteritis 9/13 periarteritis 11/13. @RheumNow #ACR22 Abstr#1571 https://t.co/At7Gw2kRUp https://t.co/zcXc6oUS0f
Richard Conway RichardPAConway ( View Tweet)
Singh @NamrataRheum et al. 27,421 RA patients, 8225 on b/tsDMARD. b/tsDMARDs did not increase risk of lymphoma. IR 1.68/1000PY (95% CI 1.5-1.9) on csDMARD vs IR 1.73/1000PY (95%CI 1.4-2.1) on b/tsDMARD. @RheumNow #ACR22 Abstr#1210 https://t.co/3Uvz3mvsGM https://t.co/6k3Vqb21KF
Richard Conway RichardPAConway ( View Tweet)
Are preexisting autoimmune dx pts okay for
PD-1i/CTLA-4i combo immunoRx
(vs PD-1i single agent)?
Common question in practice for your rheum pts who get cancer
Combo ICI means:
de novo irAE: double risk
flares: same risk
Give our pts what they need!
ABST0757 #ACR22 @RheumNow https://t.co/Vs1AoM54Ut
David Liew drdavidliew ( View Tweet)
Ab1508 #ACR22 Enthesitis on PET/CT
20 untreated PsA pts w/ total body PET/CT
All 20 (100%) pts had entheseal inflammation
127/543 (~1/4) entheses showed inflammation
@RheumNow https://t.co/OQCBWW70bt
Eric Dein ericdeinmd ( View Tweet)
Zheng et al. Celiac disease more common in SLE aOR 2.88 (95%CI 2.60 –3.31). More common in white females. Assoc higher hospitalization cost and increased LOS @RheumNow #ACR22 Abstr#1192 https://t.co/kdwLmpIxNN https://t.co/ZdQJQn3QIF
Richard Conway RichardPAConway ( View Tweet)
Abs 1011 examined fracture incidence rates in AS patients over time in VA cohort
- Rate of fractures in AS pts 2.1 per 1000 PY --> 22.8 (1999 --> 2021) vs Comparators 0.4 --> 8.3
- Post TNF era fracture rates increased AS > comparators
@RheumNow #ACR22 https://t.co/eUxoTavHGV
Akhil Sood MD AkhilSoodMD ( View Tweet)
Table by @CuoghiE on how long to wait off #teratogenic meds before trying to conceive: note 2 years fr leflunomide unless a cholestyramine washout is done #ReproductiveRheum #ACR22 @rheumnow https://t.co/l4hIBQ5XN5
TheDaoIndex KDAO2011 ( View Tweet)
A future rheumatologist attending the #ACR22 Plenary session virtually to keep up with the latest information. @RheumNow https://t.co/ttYr4iwTB8
Jonathan Kay, MD RheumKay ( View Tweet)
Barroso-García et al. ADA vs IFX vs TCZ in severe ocular Behcets with refractory cystoid macular edema. Remission 76% (ADA), 60% (IFX), 67% (TCZ). @RheumNow #ACR22 Abstr#1564 https://t.co/pRVgIdGAGS https://t.co/gOb5wQ9pHv
Richard Conway RichardPAConway ( View Tweet)
Does Bimekizumab, anti-IL17F, work in PsA? #ACR22 @RheumNow
Abstract #L02
💊Phase 3, randomized, placebo-controlled study
💉Biologic naive patients
✋ Week 52: 53-54% BKZ groups achieved ACR502 (v. 50% in TNFi)
📍benefits sustained to week 52
🛑No new safety signals
Catherine Sims, MD DrCassySims ( View Tweet)
Phase 2 efficacy and safety of deucravaticinib (TYK2i) in mod-severe SLE. Met primary endpoint (SRI4) for 3mg and 6mg doses (but not 12mg). No signal for HZ but increased oral herpes. Bigger numbers will be helpful.
@RheumNow #ACR22 #plenary #ACRBest https://t.co/SjW1OSQzdM
Julian Segan JulianSegan ( View Tweet)
PJP occurs in pts w/ AAV who undergo treatment w/ CYC or RTX, but PJP PPX assoc'd w/ inc incidence of medication-related adverse events. Abs 1081 #ACR22 @RheumNow https://t.co/7vMgx7eMAP https://t.co/bhKPtJBMAO
Dr. Rachel Tate uptoTate ( View Tweet)
DEUC showed statistically significant and sustained clinical efficacy in SRI(4) responses versus PBO and was well tolerated in SLE. Plenary Abs 1117 #ACR22 @RheumNow https://t.co/iHPiA8FCwO https://t.co/A0FQ7zwL64
Dr. Rachel Tate uptoTate ( View Tweet)
#ACR22 Plenary II Abstr#1117 Phase 2 results +ve in #lupus! Patients (65% White) on Deucravacitinib, TYK2-i had more SRI-4 response rates vs PBO. PBO:34.4%; DEUC 3 mg BID:58.2%, DEUC 6 mg BID:49.5%, DEUC 12 mg QD:44.9%. No major safety, slight increase in oral herpes @RheumNow https://t.co/QIJfoeP4dg
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
From my colleague @aili_yoyo. Mimics of vasculitis picked up on imaging. "Isolated abdominal vasculitis" is a surprisingly common consult. Can be tricky sometimes.
@RheumNow #ACR22 #mimics https://t.co/QfeaTHHzdA
Julian Segan JulianSegan ( View Tweet)
Rheumatic Masqueraders: Mimics of Rheumatic Diseases
Mimics of Vasculitis by
- Demographics
- Vascular Distribution
-**Imaging
- Labs
- Clinical Presentation
#ACR22 @RheumNow https://t.co/o0pZoiMqI2
Akhil Sood MD AkhilSoodMD ( View Tweet)